Surrozen (Surrozen) Cyclically Adjusted PB Ratio : (As of Apr. 29, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Surrozen Cyclically Adjusted PB Ratio?

Surrozen does not have a history long enough to calculate Cyclically Adjusted Book per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PB Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation

Surrozen Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Surrozen's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surrozen Cyclically Adjusted PB Ratio Chart

Surrozen Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cyclically Adjusted PB Ratio

Surrozen Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cyclically Adjusted PB Ratio	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of Surrozen's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Surrozen's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Surrozen's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Surrozen's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Surrozen's Cyclically Adjusted PB Ratio falls into.

Surrozen Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Surrozen does not have a history long enough to calculate Cyclically Adjusted Book per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PB Ratio for this company.

Surrozen (NAS:SRZN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.

Surrozen Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Surrozen's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Surrozen (Surrozen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Surrozen Inc (NAS:SRZN) » Definitions » Cyclically Adjusted PB Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

171 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

https://www.surrozen.com

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), and SZN-043 (E3/ASGR1, SWEETS).

Executives

Yang Li	officer: Exec. Vice President, Research	C/O SURROZEN, INC., 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Anna Berkenblit	director	830 WINTER STREET, WALTHAM MA 02451
Eric Bjerkholt	director	132 PURDURE AVENUE, KENGSINGTON CA 94708
Blutt Mitchell J Md	director, 10 percent owner	1370 AVENUE OF THE AMERICA, SUITE 3301, NEW YORK NY 10019
Christopher Y Chai	director	2400 BAYSHORE PARKWAY, SUITE 200, MOUNTAIN VIEW CA 94043
Mary Haak-frendscho	director	171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Wen-chen Yeh	officer: Chief Scientific Officer	171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
House Joshua Cory	other: Former VP Business Development	C/O CONSONANCE-HWF ACQUISITION CORP, 1 PALMER SQUARE, SUITE 305, PRINCETON NJ 08540
Geertrui Vanhove	officer: Chief Medical Officer	1333 S. SPECTRUM BLVD #100, CHANDLER AZ 85286
Charles O Williams	officer: Chief Financial Officer	C/O HERITAGE FINANCIAL GROUP, 721 NORTH WESTOVER BOULEVARD, ALBANY GA 31707
Mace Rothenberg	director	171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Donald J Santel	other: Former Director	4362 24TH STREET, SAN FRANCISCO CA 94114
David J Woodhouse	director	630 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Column Group Iii Gp, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158